Gaush Meditech Ltd. AI Stock Analysis
Want to see HK:2407 full AI Analyst Report?
Gaush Meditech Ltd. (2407) AI Stock Analysis
Gaush Meditech Ltd.
(HKEX:2407)
The score is supported primarily by a substantially strengthened balance sheet and attractive valuation. These positives are offset by weakening revenue and profitability, declining free-cash-flow momentum, and mixed technical signals.
Gaush Meditech Ltd. (2407) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 723.91M
- Dividend Yield
- 6.10%
- Average Volume (3M)
- 16.70K
- Price to Earnings (P/E)
- 8.0
- Beta (1Y)
- 0.72
- Revenue Growth
- -5.14%
- EPS Growth
- -22.72%
- Country
- Hong Kong
- Employees
- 893
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Gaush Meditech Ltd. Business Overview & Revenue Model
Company Description
Gaush Meditech Ltd., alongside its affiliates, is engaged in the global research, development, manufacturing, and sale of specialized medical devices for ophthalmology, serving markets both within the People's Republic of China and internationally. T...
Gaush Meditech Ltd. Financial Statement Overview
Summary
Balance-sheet improvement and positive operating cash flow support the score, but declining 2025 revenue, lower net margins, negative free-cash-flow growth, and tight coverage ratios weigh on performance.
Income Statement
65PositiveBalance Sheet
82Very PositiveCash Flow
58Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.32B | 1.38B | 1.43B | 1.41B | 1.25B | 1.30B |
| Gross Profit | 606.22M | 633.20M | 663.39M | 691.60M | 625.34M | 609.47M |
| EBITDA | 177.26M | 203.47M | 276.49M | 374.31M | 292.78M | 303.38M |
| Net Income | 75.51M | 96.19M | 92.39M | 173.52M | -349.62M | -190.45M |
Balance Sheet | ||||||
| Total Assets | 2.45B | 2.63B | 2.57B | 2.84B | 2.72B | 2.43B |
| Cash, Cash Equivalents and Short-Term Investments | 358.11M | 440.94M | 518.99M | 833.04M | 814.16M | 609.00M |
| Total Debt | 402.50M | 507.37M | 552.24M | 664.36M | 756.00M | 2.62B |
| Total Liabilities | 788.06M | 921.65M | 978.12M | 1.15B | 1.23B | 3.06B |
| Stockholders Equity | 1.65B | 1.69B | 1.58B | 1.68B | 1.47B | -656.43M |
Cash Flow | ||||||
| Free Cash Flow | 126.15M | 110.47M | 26.57M | 203.44M | 186.41M | 136.44M |
| Operating Cash Flow | 150.10M | 144.23M | 107.78M | 249.04M | 234.42M | 164.49M |
| Investing Cash Flow | -49.19M | 20.82M | 18.55M | -167.65M | -136.04M | 79.83M |
| Financing Cash Flow | -137.73M | -206.60M | -303.09M | -189.94M | 3.08M | 72.84M |
Gaush Meditech Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2407, the sentiment is Positive. The current price of 4.91 is above the 20-day moving average (MA) of 4.27, above the 50-day MA of 4.42, and below the 200-day MA of 5.19, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 70.15 is Negative, neither overbought nor oversold. The STOCH value of 92.74 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2407.
Gaush Meditech Ltd. Peers Comparison
Overall Rating
HK:178977Outperform- HK:240769Neutral
HK:223560Neutral
HK:999645Neutral
HK:250044Neutral
HK:216043Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1789 | 77Outperform | HKD 5.28B | 11.93 | 13.24% | 2.47% | 16.15% | 31.89% |
| HK:2407 | 69Neutral | HKD 726.87M | 8.03 | 4.52% | 6.10% | -5.14% | -22.72% |
| HK:2235 | 60Neutral | HKD 2.85B | 28.07 | 4.08% | ― | 94.80% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:9996 | 45Neutral | HKD 2.69B | -16.19 | -7.65% | ― | 21.23% | 36.89% |
| HK:2500 | 44Neutral | HKD 449.83M | -0.80 | -28.24% | ― | -38.15% | 25.70% |
| HK:2160 | 43Neutral | HKD 1.63B | -0.86 | -6.69% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2407 | Gaush Meditech Ltd. | 4.91 | -4.19 | -46.04% | |
| HK:9996 | Peijia Medical Ltd. | 4.03 | -2.11 | -34.45% | |
| HK:1789 | AK Medical Holdings Ltd. | 4.77 | -1.02 | -17.56% | |
| HK:2160 | MicroPort CardioFlow Medtech Corp. | 1.28 | -4.52 | -77.93% | |
| HK:2235 | MicroTech Medical (Hangzhou) Co., Ltd. Class H | 6.70 | 0.04 | 0.60% | |
| HK:2500 | Venus Medtech (Hangzhou), Inc. Class H | 1.00 | -1.33 | -57.08% |
Gaush Meditech Ltd. Corporate Events
Gaush Meditech Profit Slumps on Softer Revenue as R&D Intensity Remains High
Gaush Meditech reported interim revenue of RMB595.1 million for the six months ended June 30, 2026, down 8.9% year on year, as net profit fell 57.9% to RMB15.1 million and basic earnings per share declined to RMB0.12. Despite tighter top-line and pro...
Gaush Meditech Sets Board Meeting to Approve 2026 Interim Results and Consider Dividend
Gaush Meditech Ltd has scheduled a board meeting for August 28, 2026 to review and approve the group’s interim results for the six months ended June 30, 2026 and to authorize their publication. The board will also consider the declaration of an inter...
Gaush Meditech Grants Heidelberg Exclusive Global Rights to T3 Corneal Imaging System
Gaush Meditech’s subsidiary Gaush Neotech has signed a five-year exclusive agency agreement with Germany’s Heidelberg Engineering to distribute its T3 corneal confocal microscopy system globally, excluding mainland China. Under the deal, Heidelberg w...
Gaush Meditech Updates Cayman Registered Office in Corporate Charter
Gaush Meditech Ltd has updated its seventh amended and restated memorandum and articles of association to reflect the change in its principal share registrar and transfer office in the Cayman Islands. The registered office address now identifies Asce...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026